10 May 2017
: Case report
Obinutuzumab is Effective in Chronic Lymphocytic Leukemia and Rheumatoid Arthritis After Rituximab Failure: A Case Report
Unusual or unexpected effect of treatment, Unexpected drug reaction, Educational Purpose (only if useful for a systematic review or synthesis), Rare coexistence of disease or pathology
Curtis Lachowiez1BDEF*, Atul Deodhar2BE, Eliana Kozin3B, Stephen Spurgeon3BDEDOI: 10.12659/AJCR.903747
Am J Case Rep 2017; 18:516-519
Abstract
BACKGROUND: Chronic lymphocytic leukemia (CLL) is the most common leukemia affecting older adults. As such, many of these patients suffer from co-existing disease states, and the provider must take these comorbidities into account when determining a treatment regimen. The widespread use of monoclonal antibodies (mAbs) has drastically changed the treatment landscape of multiple diseases, ranging from leukemia to autoimmune conditions such as rheumatoid arthritis.
CASE REPORT: We present the case of a patient who had progression of his CLL and rheumatoid symptoms on rituximab therapy, and was subsequently treated with the second-generation anti-CD20 antibody obinutuzumab. Obinutuzumab therapy was associated with simultaneous sustained remission of both disease states, allowing for discontinuation of all other disease-modifying anti-rheumatic drugs (DMARDs), and prolonged remission of his CLL.
CONCLUSIONS: While anti-CD20 antibodies have a clear role in the treatment of leukemia and inflammatory conditions, the success of obinutuzumab in RA has not been fully evaluated. We present this case as further evidence of the strong role of anti-CD 20 therapy in multiple conditions, and the unique opportunity for control of simultaneous disease states through targeted inhibition of shared common pathways.
Keywords: Arthritis, Rheumatoid, Leukemia, Lymphocytic, Chronic, B-Cell, Medical Oncology
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.948238
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.947782
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.947794
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.947096
Most Viewed Current Articles
21 Jun 2024 : Case report
100,489
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
53,790
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133
20 Nov 2023 : Case report
36,376
DOI :10.12659/AJCR.941424
Am J Case Rep 2023; 24:e941424
07 Jul 2023 : Case report
25,034
DOI :10.12659/AJCR.940200
Am J Case Rep 2023; 24:e940200